In the News
As Imaging Biometrics expands both its cutting-edge products and world-class services, articles and news releases continue to highlight these successes. Below are collection of press releases, articles, and other links pertaining to Imaging Biometrics.
Standardized rCBV - A Reproducible Imaging Biomarker
Standardized rCBV (sRCBV) measures, available exclusively in IB Neuro, give the best results n terms of accuracy and repeatability.
rCBV threshold distinguishes radiation effect from GBM
This further affirms the accuracy and reproducibility of IB Neuro's perfusion parameters as proven imaging biomarkers, and gets us closer to standardizing on one perfusion approach.
IB Neuro Proves Superior in Head to Head Competition
The results showed that IB Neuro outperformed NordicICE in terms of accuracy, its ability to distinguish tumor from treatment effects, and its correlation between rCBV and histologic microvessel volume.
ACRIN Trial Adds Evidence that rCBV Correlates With Overall Survival
Imaging Biometrics, LLC (IB), proudly announces the results of a recently published multicenter American College of Radiology Imaging Network (ACRIN) trial. It was the first advanced imaging study of its kind to be performed in a multicenter trial setting.
Imaging Biometrics Introduces IB DCE
Imaging Biometrics, LLC (IB), has announced the release of IB DCE. Users can choose among multiple DCE processing approaches including the Patlak, Tofts, and extended Tofts models. Driven by client feedback, IB DCE operates like other IB products and provides users flexible processing options. It also has built-in automated and semi-automated features for rapid integration in clinical workflows.
Imaging Biometrics Announces Upgrades
Imaging Biometrics, LLC (IB), a biotechnology company specializing in the development of software solutions for advanced visualization and analytics, today announced that it has released version 1.2 of its IB Clinic software package. The enhancements further differentiate IB Clinic as an elite array of perfusion, diffusion and advanced imaging solutions.
Imaging Biometrics Issued Patent
Imaging Biometrics, LLC (IB), a biotechnology company specializing in the development of software solutions for advanced visualization and analytics, today announced that it has been issued a US patent covering a unique MRI technology. No other technology enables the collection of both DSC and DCE data at the same time. Providing twice the information using half the resources is a huge step in helping hospitals improve patient care while fighting rising costs.
Imaging Biometrics Joins National Imaging Network
Imaging Biometrics, LLC (IB), a biotechnology company specializing in the development of software solutions for advanced visualization and analytics, announced its participation in a national network of imaging investigators focused on translating novel imaging technologies from leading institutions across the country.
Austin Radiological Association Installs IB Rad Tech™
Imaging Biometrics, LLC (IB), a biotechnology company specializing in the development of software solutions for advanced visualization and analytics, announced that Austin Radiological Associates has installed the recently released IB Rad Tech to enable the ability to accurately monitor tumor progression for patients with brain tumors.
aycan Introduces New Neuro/Oncology Workstation
aycan, a recognized worldwide leader in medical imaging, expands its portfolio of specialty imaging workstations with the introduction of aycan Neuro/Oncology workstation. Designed for neuro-oncology applications, the new workstation is powered by aycan workstation OsiriX PRO, and FDA 510(k) cleared plug-ins from partner company Imaging Biometrics, LLC.
Imaging Biometrics Clinic Receives FDA Clearance
Imaging Biometrics, LLC (IB), a biotechnology company specializing in the development of software solutions for advanced visualization and analytics, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration for IB Clinic™, a post-processing perfusion, diffusion, and image analysis toolkit.
Imaging Biometrics Passes ISO Audit
Imaging Biometrics, LLC (IB), a biotechnology company specializing in the development of advanced medical image analysis software, announced today that it has been recertified by the International Organization for Standardization (ISO) in an independent audit.
Imaging Biometrics Earns ISO 13485:2003 Certification
Imaging Biometrics, LLC (IB), a biotechnology company specializing in the development of advanced medical image analysis software, announced today that it has earned the International Organization for Standardization’s (ISO) 13485:2003 certification.
Imaging Biometrics Releases Enhanced Version of IB Neuro v1.0
Imaging Biometrics LLC (IB), a biotechnology company specializing in the development of advanced visualization software, will reveal an upgraded version of its magnetic resonance imaging (MRI) perfusion software, IB Neuro™, at the upcoming RSNA meeting in Chicago. IB will highlight several new features that will help facilitate personalized care for patients with brain disorders as well as increase the productivity of busy healthcare facilities.
Imaging Biometrics is Awarded Phase II SBIR from NIH
Imaging Biometrics LLC (IB), a biotechnology company specializing in the development of medical imaging software, has announced that it has received $800,000 in a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) for the continued development and distribution of novel and proven perfusion and diffusion analysis software for the evaluation of brain tumors and stroke.
Imaging Biometrics and University of Pennsylvania Enter into Exclusive License Agreement
Imaging Biometrics, LLC (IB), a provider of advanced visualization and analytical software solutions for the medical industry, is pleased to announce the signing of an exclusive, global license agreement with the University of Pennsylvania.
Imaging Biometrics and the Medical College of Wisconsin Awarded NIH Grant
Imaging Biometrics, LLC (IB) and investigators at The Medical College of Wisconsin in Milwaukee have been awarded a Phase I STTR grant from the National Institutes of Health (NIH) to develop much-needed magnetic resonance (MR) image analysis tools for reliable and automated determination of brain tumor burden. The result of this combined effort will be the integration of key technologies into an easy-to-use application which may significantly enhance accuracy in evaluating a tumor’s response to various treatment therapies.
IB Neuro Correlates with Stereotactic Biopsied Tissue Samples
A preliminary study, led by cancer researchers at Barrow Neurological Institute at St. Joseph’s Hospital and Medical Center (BNI-SJHMC) and Imaging Biometrics LLC (IB), has validated a magnetic resonance imaging perfusion (pMRI) technology with stereotactic tissue biopsy results.
ACRIN Enters Agreement with Imaging Biometrics
Imaging Biometrics, LLC (IB), a provider of advanced visualization and analytical software solutions, has an agreement with the American College of Radiology Imaging Network (ACRIN) to evaluate magnetic resonance imaging (MRI) datasets using its proprietary dynamic susceptibility contrast (DSC) MR perfusion software, IB Neuro™.
FDA Clears imaging Biometrics MR Perfusion Software, IB Neuro™
Imaging Biometrics, LLC (IB), a provider of advanced visualization and analytical software solutions, today announced it has received FDA 510(k) clearance by the Food and Drug Administration for the company’s new magnetic resonance imaging (MRI) perfusion software, IB Neuro™.
